AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
23 janv. 2025 08h50 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
22 janv. 2025 08h30 HE
|
AIM ImmunoTech Inc.
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06 déc. 2024 09h15 HE
|
AIM ImmunoTech Inc.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
06 nov. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
11 sept. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that an analysis of the complete clinical patient data from the AMP-518 clinical...
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
15 avr. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29 févr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
08 août 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
10 juil. 2023 08h05 HE
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
30 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...